Status:
COMPLETED
LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy
Lead Sponsor:
Kyungpook National University Hospital
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
60-80 years
Brief Summary
This study is to investigate whether there is an association of the LOC387715/HTRA1 variants with response to treatment with combined photodynamic therapy and intravitreal bevacizumab for patients wit...
Detailed Description
This is a retrospective cohort study comprised of 70 eyes being treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections. Patients were ...
Eligibility Criteria
Inclusion
- patients older than 60 years of age at onset
- polyp-like terminal aneurysmal dilations with or without branching vascular networks in indocyanine green angiography (ICGA) and subretinal reddish-orange protrusions corresponding to polyp-like lesions
- patients who had combined photodynamic therapy and intravitreal bevacizumab injections, and followed up for more than 12 months after the first treatment
Exclusion
- patients with retinal or choroidal diseases including pathologic myopia, angioid streaks, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, and other secondary CNV
- patients who refused genotypic analyses
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01233115
Start Date
October 1 2010
End Date
August 1 2011
Last Update
August 30 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
In Taek Kim
Daegu, Kyungsangpookdo, South Korea, 700-721